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Abstract Preclinical cardiovascular research using noninva-
sive radionuclide and hybrid imaging systems has been
extensivelydevelopedinrecentyears.Singlephotonemission
computed tomography (SPECT) is based on the molecular
tracer principle and is an established tool in noninvasive
imaging. SPECT uses gamma cameras and collimators to
form projection data that are used to estimate (dynamic) 3-D
tracer distributions in vivo. Recent developments in multipin-
hole collimation and advanced image reconstruction have led
to sub-millimetre and sub-half-millimetre resolution SPECT
in rats and mice, respectively. In this article we review
applications of microSPECT in cardiovascular research in
which information about the function and pathology of the
myocardium, vessels and neurons is obtained. We give
examples on how diagnostic tracers, new therapeutic inter-
ventions, pre- and postcardiovascular event prognosis, and
functional and pathophysiological heart conditions can be
explored by microSPECT, using small-animal models of
cardiovascular disease.
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Introduction
Small-animal models ofcardiac diseaseplayanimportant role
in cardiovascular research, and the ability to translate the
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The use of radionuclide imaging in small animals has
provided many advantages for researchers to investigate in
vivo molecular processes in cardiovascular pathology. Small-
animal single photon emission computed tomography
(SPECT) systems are now used by many centres for tracer
development, therapy evaluation and pathophysiology inves-
tigations. Here we discuss the basic principles and preclinical
applications of microSPECTand combined microSPECT/CT
in cardiovascular research.
Background of microSPECT and microSPECT/CT
SPECT is based on the molecular tracer principle and
detection of gamma rays by radiolabelled molecules. The
suitable energy range of gamma rays for clinical SPECT is
typically around 60–300 keV. Due to the small size of rats
and mice, isotopes with much lower energies (e.g.
125I, with
27–35 keV) can be employed in microSPECT, which would
not be useful for imaging in patients. For obtaining
tomographic images, tens up to hundreds of projection
images of the animal are acquired with position-sensitive
gamma-detectors. Today almost all small-animal SPECT is
performed with pinhole collimators, since these collimators
provide a much better noise resolution trade-off in small
objects than parallel hole or fan-beam collimators that are
commonly used in clinical cardiac SPECT. Most small-
animal SPECT systems rotate either the detector and
collimator or the object [4–12]. Stationary small-animal
pinhole SPECT systems [13–17] do not need to be rotated
since they use detector set-ups that cover 360° and many
pinholes to provide a large number of projection angles
under which the animal is observed. They also have the
advantage that dynamic imaging is possible with arbitrarily
short frame lengths [15, 18, 19].
The full360°coverageincombinationwithmanyfocusing
micropinholes and a high magnification factor to maximize
the information content per photon provide a very high
reconstructed image resolution. Multiple projections from
different angles that can be acquired at the same time in such
systems facilitate excellent ECG-gated myocardial imaging in
rats and mice, which have heart rates of around 300 and 600
beats per minute, respectively. For instance, the U-SPECT-II
system (MILabs, The Netherlands) has 75 pinholes on its
interchangeable cylindrical collimators (Fig. 1), and is based
on three ultralarge NaI scintillation gamma-cameras. Recon-
structed images can reach resolutions of ≤0.35 mm and
0.45 mm anywhere in the body using the mouse collimators
with 0.35 mm and 0.6 mm gold pinhole apertures,
respectively, and ≤0.8 mm with the standard total body rat
collimator. It is expected that dedicated high-resolution
detectors will contribute to further improvement in multipin-
hole SPECT resolution, thereby expanding the field of
application of microSPECT. In addition, dedicated collima-
tors to image specific organs are under development, and
these can dramatically boost performance. Overviews and
primers of pinhole SPECT technology have been provided
by some investigators [20, 21].
In contrast to PET, dual-tracer or triple-tracer images can
be readily obtained with SPECT. Multitracer imaging results
in shorter acquisitiontimesand perfect registration of images
in space and time, and each tracer represents a different
biological process. Another advantage of SPECT is that
radiotracers can be produced more easily in the laboratory
without the need for a cyclotron, so that the cost-
effectiveness of SPECT is higher than that of PET. Clinical
PETsystems have a much higher resolution than SPECT, but
this is reversed for microSPECT since the best resolution of
commercial microPET systems is still above 1 mm [22, 23].
Perfusion SPECT provides valuable information for the
diagnosis of patients with coronary artery disease (CAD).
For example, in triple vessel disease, in which tracer
delivery to the whole myocardium is diminished due to
Fig. 1 a) Separate U-CT system and U-SPECT-II system. b)
Integrated U-SPECT-II/CT system
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as normal in qualitative or semiquantitative image analysis
because comparison of the defective area with the region of
the most intense uptake will not show any difference from
normal. Absolute quantification of tracer uptake, which
measures megabecquerels of tracer uptake per gram of
tissue, can solve this problem [24]. The most prominent
obstacles to absolute quantification in clinical SPECT used
to be photon absorption and scattering, but today these
problems are much smaller: SPECT systems equipped with
transmission sources or, more recently, integrated with CT
scanners are on the market [25–28]. These allow accurate
correction for attenuation, and also use accurate methods to
correct for scatter and collimator and detector blurring [29–
38]. Cardiac and respiratory movements also degrade
quantification, but both could be dealt with through (dual)
gating as used in microPET imaging [39]. Although
significant technical improvements for absolute quantifica-
tion of myocardial perfusion using microSPECT have been
introduced in recent years, the “roll–off” phenomenon with
typical commercial SPECT perfusion agents under hyper-
aemic conditions, even in humans with less myocardial
blood flow than mice, still remains a limitation for accurate
measurement in myocardial perfusion imaging.
Quantification errors due to scatter and attenuation do
degrade small-animal studies to a much lesser extent than in
clinical SPECT because of less photon attenuation in small
bodies (about 25% in the centre of a rat body when imaging
with
99mTc [40]). MicroCT imaging is able to provide
photon attenuation information which can be used for
nonuniform attenuation correction in microSPECT. How-
ever, several studies [40, 41] have shown that uniform
attenuation correction (which may be based on the animal’s
body contour) may reduce quantification errors from more
than 10% to less than 5%. Therefore, a CT scan that adds
dose and needs additional scanning equipment and scan
time may be unnecessary. A webcam-based correction has
been proposed [41].
Multimodal imaging can rely on separate devices (Fig. 2a)
in which images are fused through markers [42, 43], or
marker-free methods in which the spatial relationship
between beds is known through calibration [42, 44]. The
accuracy of registration can be very satisfactory (0.2 mm),
and an advantage is that SPECT and CT can be used in
parallel, and are individually upgradable. Also registration
with other systems such as MRI can be based on the same
principles. The advantage and disadvantages of both
approaches have been discussed [34, 45].
An attractive aspect of high-resolution integrated micro-
SPECT/CT devices [46–49] (e.g. Fig. 2b) is that the bed
with the fixed animal does not have to be moved from one
scanner to another. Integrated SPECT/CT, in which the bed
moves through both the SPECT and the CT scanner is very
convenient, although this approach is hard to extend to
MRI, and image registration is still needed to obtain
accurately matched combined images.
The translatability of the cardiovascular systems of small
animals including mice and rats to the human cardiovascu-
lar system and the exceptional characteristics of modern
microSPECT and multimodality imaging approaches pro-
vide promising opportunities in preclinical cardiovascular
research. Novel microSPECT systems can provide quanti-
tative images, and can perform longitudinal studies in the
same animal, a high pinhole magnification factor resulting
in high resolution, possibly dynamic imaging, and multi-
tracer imaging. MicroSPECT and microSPECT/CT systems
have a wide range of applications in preclinical cardiovas-
cular research, including investigation of myocardial left
ventricular (LV) parameters such as ejection fractions and
volumes, cardiac innervation parameters, vascular and
atherosclerosis parameters, and the timing of administration
and dose of novel radiotracers and biomarkers.
Fig. 2 U-SPECT gated mouse
cardiac perfusion images
obtained in a normal C57BL/6
mouse (ED end diastole, ES end
systole)
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Left ventricular function
In order to assess the functional condition of the heart in
transgenic mouse models in vivo, small-animal heart
imaging can be used for verifying phenotypic differences
as well as assessing the benefits of certain therapies. The
ability to acquire gated images in small rodents which have
high heart rates has eliminated the heart motion effect
(Fig. 2). It has been shown that
99mTc-labelled radio-
pharmaceuticals, which are routinely used for SPECT
imaging in humans, can demonstrate viable tissue and
perfusion status in animal models of ischaemia/reperfusion
[14]. Further studies have demonstrated that myocardial
perfusion defects are correlated with the true size of the
defect, and can be analysed quantitatively as well as
qualitatively [50, 51]. Liu et al. used animal models of
myocardial ischaemia with coronary artery ligation and
acquired images after
99mTc-sestamibi injection. The area
where no uptake was seen corresponded with the infarcted
tissue which was confirmed by triphenyl tetrazolium
chloride (TTC) [14].
Cardiac and respiratory motion can always affect image
resolution in SPECT and CT. In order to overcome this
problem gating (cardiac and/or respiratory) is performed to
synchronize the acquisition of projected data at the same
time of the cardiac cycle. Gating also offers the chance to
simultaneously map LV perfusion and assess LV function in
clinical SPECT applications. ECG-gated microSPECT has
been implemented in recent years. It has been shown that
preclinical ECG-gated perfusion SPECT (in mice) permits
quantification of LV volumes and motion as well. This is
also a result of advances in image reconstruction software
[52, 53]. The noninvasive nature of the test allows repeated
studies in the same animal for follow-up studies [54].
Necrosis visualization
The development of necrotic tissue-avid tracers may help
early detection of myocardial infarction (MI) noninvasively.
In vivo visualization of necrotic tissue may also provide a
quantitative index for evaluating the antinecrotic effect of
drugs in development in animal models of ischaemic heart
disease.
Glucarate is a small molecular weight compound, a six-
carbon dicarboxylic acid sugar, which has affinity for
histone proteins. In necrotic cells, due to lesions in the
cellular and nuclear membranes,
99mTc-glucarate can bind
to histone proteins and be retained in the tissue [55]. It has
been shown that only minimal levels of glucarate bind to
normal myocardial cells and viable ischaemic cells. Further
studies have illustrated the possibility of immediate
postinjection imaging with
99mTc-glucarate due to its rapid
blood clearance [56]. Thus, by using
99mTc-glucarate as a
SPECT tracer, necrotic cells can be depicted to provide data
in acute coronary syndrome. Additionally, imaging of
infarcts is possible within minutes of occlusion [57–59].
Moreover, it has been shown, by comparative investigations
using TTC staining, that SPECT images of
99mTc-glucarate
uptake allow accurate assessment of infarct size. Converse-
ly, it has been shown that there is no glucarate uptake in old
necrotic myocardial tissue. Although glucarate uptake in
necrotic tissue occurs as early as 3 hours after ischaemia/
reperfusion, at 10 days after necrosis there is no obvious
tracer uptake in the heart [60].
Some studies have focused on other necrotic tissue-avid
tracers than glucarate compounds. Porphyrin derivatives
were initially developed as tracers for tumour cell tracking.
Reports of the avidity of porphyrin derivatives for necrotic
tissue [61–63] and studies on their use in visualization of
infarcted tissue by MRI led to efforts to radiolabel hyper-
icin. Hypericin is a natural substance with a biological
activity similar to that of porphyrin. Both substances are
known to be photosensitizers and have been used in
antitumour therapies [64]. Ni et al. synthesized mono-
[
123I]iodohypericin (MIH) and injected it into rabbit models
of MI. SPECT imaging compared to TTC staining and
autoradiography confirmed the accumulation of [
123I]MIH
in the infarcted tissue [65]. In addition, due to the minimal
levels of tracer uptake in normal myocardium, the target to
nontarget tracer concentration ratio was very high. In
another study, Fonge et al. compared the results of [
123I]
MIH microSPECT with the results of [
13N]ammonia
microPET in rabbit models of MI. There was a correlation
between areas with low blood flow in microPET and [
123I]
MIH uptake in microSPECT [66].
Apoptosis visualization
Apoptotic cell death has been the subject of many studies
investigating opportunities for therapeutic interventions.
Apoptosis is an energy-requiring highly regulated form of
cell death which is characterized by cell shrinkage, DNA
fragmentation, caspase activation, membrane blebbing, and
phosphatidyl serine (PS) externalization. It has been
demonstrated that reperfusion injury in the heart leads to
apoptotic cell death [67–70]. The role of apoptotic cell
death in heart failure has also been investigated in many
studies [71–73]. The development of radiopharmaceuticals
that bind to apoptotic cells has been useful for in vivo
evaluation of therapeutic efforts in apoptotic cell death in
cardiomyocytes. Annexin A5, a 36-kDa physiological
protein, has affinity for binding to the externalized PS.
99mTc-Annexin A5 has been used as a SPECT tracer in
recent years for detecting apoptosis in the preclinical and
Eur J Nucl Med Mol Imaging (2010) 37:1766–1777 1769clinical settings in vivo.
99mTc-Annexin A5 uptake has been
confirmed by apoptosis-specific immunohistochemistry
assays [74–80]. Nevertheless, PS exposure has been shown
not to be specific for apoptotic cell death. In necrosis as well,
due to leakage in the cell membrane, PS can be exposed and
bound to annexin A5. Annexin A5 can visualize apoptotic
PS externalization specifically, if used with a second marker
showing an intact cell membrane [81].
More recently, a new
99mTc-bound, PS-avid agent has
been developed. The C2A domain of synaptotagmin, which
binds to PS in a calcium-dependent manner, has been
shown to be sensitive for cell death detection [82]. False-
positive uptake, due to some extent to PS exposure in other
forms of cell death, led investigations to find more specific
tracers for apoptosis visualization. Caspase-3, altered
membrane permeability, and several enzymes which are
responsible for apoptosis, are appropriate potential targets
for apoptosis imaging.
Stem cell therapy evaluation
The recent treatment strategy for cell-death-related heart
disease, cellular cardiomyoplasty, needs to be evaluated in
preclinical investigations. The most important objectives
for the investigations are the optimal cell type, route of
delivery, number of cells, suitable timing after infarction,
and future monitoring of grafted cells. Imaging modalities
may help stem cell therapy in the heart in three ways,
including tracking and quantification of transplanted cells,
assessment of function and differentiation, and monitoring
of underlying tissue status, as well as in assessing the
problems involved in the generation of suitable cell
materials [83–85]. Zhou et al. used stem cell grafts labelled
with
111In-oxyquinoline and performed double tracer
ultrahigh resolution SPECT with
99mTc-sestamibi to evalu-
ate the engraftment of the stem cells in the infarcted area
[86]. However, due to the half-life of
111In-oxyquinoline
(67.2 h) the imaging could be only done within 96 h of
engraftment, and because radioactivity in stem cells
remains in the area even after the cells have died,
quantification of uptake may overestimate the survival
fraction of injected stem cells. Thus, this method may be
useful for short-term tracking of the cells and investigating
homing strategies for engraftment.
To assess the function of the targeted cells by SPECT,
gene imaging can also be used. Gene expression can be
assessed by reporter genes. For imaging with a reporter
system, a probe is administered to the subject and
selectively bound or metabolized with the reported gene
product. This interaction results in probe trapping by the
transgenic cell and its level is proportional to the gene
expression. The result shows the functionality of the cell.
One of the reporter genes most used in this regard is herpes
simplex virus tyrosine kinase (HSV1-tk), which is absent in
mammalian cells and expresses the tyrosine kinase enzyme
that converts cytosine to uracil. Hence, only transgenic cells
which express this gene can convert 5-fluorocytosine to
5-fluorouracil, and administration of radiolabelled nucleo-
side to the subject and acquisition with SPECT will show
the tracer uptake in the area of cells expressing the reporter
gene [87].
A study on tumour cells has shown the sensitivity of
the D-isomer of
123I-2′-fluoro-2′-deoxy-1-beta-D-arabino-
furanosy-5-iodo-uracil (d-FIAU) in detecting cells positive
for HSV1-tk [77]. It has been shown in a study on Wistar
rats injected with the adenovirus-expressing hNIS gene
that imaging with iodine and technetium tracers can verify
the activity of cardiomyocytes [88]. Thus, transferring the
gene to the stem cells prior to myocardial cell transplan-
tation can aid the further tracking and monitoring of the
graft. Furthermore, for assessment of gene therapy,
coexpression of the hNIS gene with the gene of choice
has shown promise for future monitoring of cardiac gene
therapy. However, one potential obstacle in the use of
hNIS for stem cell tracking is gene silencing, which has
been reported in neurological studies [85].
Remodelling investigations
LV remodelling after MI leads to LV dysfunction and failure.
Matrix metalloproteinase (MMP), a proteolytic enzyme, has
been shown to play a causal role in this process [89]. In vivo
MMP activation imaging may provide data to quantify and
localize MMP activity and its role in further LV remodelling.
In addition, MMP imaging provides the opportunity to track
therapeutic efforts directed at MMP inhibition to reduce post-
MI remodelling. Su et al. investigated the activation of MMP
enzymes with microSPECT/CT in mice models of MI. They
used a
99mTc-bound radiotracer (RP805) to visualize MMP
in vivo and compared it to in situ zymography, and found a
good correlation between the results [90].
The role of blood coagulation factor XIII in post-MI
healing has also been studied using
111In-NQEQVSPLTLLK
[77]. The noninvasive imaging of factor XIII may help
further investigations on the assessment of factor XIII-
targeted therapies [91].
Innovative pathophysiology investigations
A better understanding of pathophysiology can shed light on
thepathologicalprocessesincardiovasculardiseases,andmay
lead to new therapeutic interventions. Animal models,
especially mice and rats, have been used traditionally for the
investigation of molecular processes in cardiovascular dis-
eases. Radionuclide imaging has significantly improved our
understanding of several aspects of pathophysiology in small
1770 Eur J Nucl Med Mol Imaging (2010) 37:1766–1777animal models. For instance the role of sigma receptors in
cardiomyocytes has been studied in recent years. Their role in
blocking the potassium channel and decreasing neuroexcit-
abilityinintracardiacneuronshasbeenreportedbyZhangand
Cuevas [92]. Sigma receptors are a largely unexplored area
of cardiology, and should be studied. Recent efforts towards
radionuclide imaging of sigma receptors in various organs
can be expanded in cardiology to better distinguish sigma
receptor function in cardiovascular systems [93].
In another investigation,
99mTc-losartan was used for
noninvasive imaging of angiotensin receptors in mouse
heart muscle cells after permanent ligation of the left
anterior descending artery [94]. Increased tracer uptake in
post-MI hearts and its correlation with remodelling showed
the role of the renin-angiotensin axis in progression of heat
failure after MI. In addition, this study demonstrated the
potential role of noninvasive imaging strategies in identi-
fication of patients likely to develop heart failure.
Cardiac innervation imaging
The autonomic nervous system plays an important role in
cardiovascular diseases. Disturbances in function and
integrity, as well as enhanced sympathetic activity may
lead to numerous heart pathologies. Therefore, evaluation
of the sympathetic innervation of the heart could provide
important data on the aetiology and progress of heart
diseases. It might also provide a tool for noninvasive
assessment of novel therapeutic approaches targeting
sympathetic nervous system activity, and also assessment
of the side effects of drugs on cardiac adrenergic function.
123I-labelled metaiodobenzylguanidine (
123I-MIBG), an
analogue of the false neurotransmitter guanethidine, has
been used clinically for sympathetic neuronal activity and
integrity since the 1980s. Presynaptic sympathetic nerve
terminals can take up and store MIBG in the same way as
norepinephrine. Thus, MIBG uptake and washout rate can
be influenced by sympathetic tone and the integrity of
nerve terminals. Studies using
123I-MIBG in animal models
of coronary artery occlusion have revealed more extended
nerve damage than myocardial injury in MI [95]. Also,
some investigations have focused on the role of denervation
in diabetic heart disease and cardiomyopathy [96].
123I-
MIBG uptake defects have also been shown to be related to
arrhythmogenesis in the heart after CAD, cardiomyopathy
and other cardiac pathologies [97]. Due to more favourable
properties of
99mTc-bound radiopharmaceuticals compared
with
123I-based tracers, Samnick et al. labelled 1-(4-
fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-
mercapto-2-methylpropylamino)-piperidine (FBPBAT)
with
99mTc and compared its characteristics in the assess-
ment of cardiac adrenergic function in the rat with those of
123I-MIBG [98]. They used rat models pretreated with α1
and β1 inhibitors and acquired SPECT images after
radiopharmaceutical incubation.
99mTc-FBPBAT showed
higher uptake than
123I-MIBG.
99mTc-FBPBAT also had
more cardiac adrenergic specificity. Moreover,
99mTc-
FBPBAT targeted postsynaptic adrenoreceptors, whereas
123I-MIBG was absorbed via a presynaptic uptake I route.
In another study, the average effective dose of
99mTc-
FBPBAT was shown to be less than half that of
123I-MIBG
[99]. These studies encourage further investigations of
99mTc-based radiopharmaceuticals for SPECT studies of
cardiac adrenergic innervation [97].
Vascular applications
Angiogenesis monitoring
Another field of study in ischaemic diseases, including
ischaemic heart disease, is the stimulation of angiogenesis
in the injured tissue. Angiogenesis is an important process
in infarct healing and post-MI LV remodelling. Thus,
noninvasive imaging of angiogenesis may improve risk
stratification in post-MI patients. Angiogenesis imaging can
also provide a tool to evaluate therapeutic interventions
aimed at angiogenesis stimulation. Integrins, a family of
cell surface receptors, are known to play a role in
angiogenesis. αvβ3 integrin-avid agents have been used
to visualize angiogenesis in postinfarct animal models.
111In- or
123I-labelled αvβ3 integrin-avid radiotracer has
been shown to be focally retained in hypoperfused
myocardial regions [58, 100]. Vascular endothelial growth
factor (VEGF) also plays a key role in angiogenesis. The
radiolabelled antibodies for VEGF have also been used for
detecting angiogenesis, especially in tumour cells. Other
detectable factors involved in the angiogenesis process,
such as activated endothelial cells and MMP, are potential
targets for radionuclide imaging of angiogenesis [100].
Plaque imaging
Rupture of atherosclerotic plaque results in severe cardiac
events in 70% of acute MIs and sudden cardiac death.
Anatomical methods of atherosclerosis imaging visualize
coronary artery stenosis, which is responsible for 20% of
plaque complications. However, the majority of acute
coronary events are a consequence of rupture and further
thrombotic occlusion in nonstenotic lesions. Criteria to
regard a plaque as rupture-prone and vulnerable have been
suggested by Naghavi et al, [101]. The important attributes
regarding injury, inflammation, thrombogenicity, proteoly-
sis, stenosis and morphology play a role in the prediction of
plaque vulnerability. The major criteria for labelling a
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macrophage and T-cell infiltration), thin cap with large lipid
core, superficial platelet aggregation, fissure, and stenosis
>90%. Apart from CT-provided data on stenosis, molecular
imaging techniques have been widely used in recent years to
depict biological processes within plaque regarding other
plaque vulnerability criteria as mentioned above [102]. It is
particularly noteworthy that the characteristics of the most
common type of vulnerable plaque are inflammatory cell
infiltration, platelet aggregation, MMP activation, large lipid
core content and apoptosis, but not significant stenosis [101].
Thus, addition of molecular imaging techniques to routine
plaque assessment procedures can potentially provide better
recognition of vulnerable atherosclerotic plaques.
Apoptosis in plaques
Apoptosis is one of the characteristics of a vulnerable
atherosclerotic lesion. It has been shown that apoptosis
occurs in smooth muscle cells and monocytes in the plaque,
and is a good target for visualizing atherosclerotic plaque,
in addition to categorizing plaques as vulnerable. In a study
on the detection of atheroma in the aorta of balloon-injured
rabbits, focal
99mTc-annexin A5 uptake was shown to be
correlated with macrophage apoptosis in the plaque [103].
Isobe et al. demonstrated that SPECT/CT imaging with
annexin A5 compounds provides appropriate correlation
between tracer uptake and apoptosis in plaques [104]. They
showed that in ApoE
−/− mice, induced atherosclerotic
plaque can be detected by
99mTc-annexin A5, and the
quantitative uptake is related to the macrophage content of
the plaque. Reduced
99mTc-annexin A5 uptake after diet
modification and simvastatin therapy has been shown in
another study [105].
Thrombogenicity
Thrombosis at the rupture site or the sites of superficial
erosions on the plaque is another marker that predicts the
vulnerability of plaque. Thrombosis visualization can help
predict future events in CAD. Fibrin detection by CT using
fibrin-targeted nanoparticles has recently been reported in
humans [106]. It can also be used in animal models of
cardiovascular diseases to evaluate therapeutic interven-
tions for thrombosis formation and dissolution.
Lipoprotein accumulation
Vulnerable plaques contain more than 40% low-density
lipoproteins in their core [101].
99mTc-labelled oxidized
low-density lipoproteins (oxLDL) allow visualization of
lipid accumulation within macrophages and foam cells.
Iuliano et al. showed rapid blood clearance and tracer
uptake by atherosclerotic plaque in humans [107]. Further
studies quantifying tracer uptake and its contribution to the
vulnerability of plaques have been performed in small-
animal models of CAD [108, 109].
Inflammation
The inflammatory nature of atherosclerosis, due to infiltra-
tion of the plaque with macrophages/monocytes and T
lymphocytes, provides a target for cell content imaging of
atherosclerotic plaques. Interleukin-2 (IL-2), labelled with
99mTc, was used by Annovazzi et al. to demonstrate T-cell
infiltration in human carotid artery atherosclerotic plaques
[110]. This study showed the accumulation of tracer in
vulnerable plaques and also demonstrated the consequent
influence of lipid-lowering on uptake. Circulating mono-
cyte recruitment in the plaque site and lipid phagocytosis
by phagocytes have also been studied as approaches to
inflammation visualization in atherosclerotic plaques.
Although most investigations in this field have been done
using microPET, the known advantages of SPECT systems
and SPECT specific tracer labelling should stimulate more
studies on plaque inflammation by microSPECT.
Proteolysis
Activation of MMP in the atherosclerotic plaque may lead
to further instability and rupture. Schafer et al. studied the
feasibility of using a
123I-labelled MMP inhibitor in a
known model of arterial remodelling and lesion develop-
ment [111]. They showed that SPECT imaging using [
123I]
I-HO-CGS 27023A can be an appropriate method for
measurement of MMP activity within the plaque. In another
study, a
99mTc-labelled broad MMP inhibitor was used to
determine the effects of statin therapy and dietary modifi-
cation on MMP activation in rabbit models of atheroscle-
rosis [112]. The microSPECT/CT results were compared
with histological and immunohistochemical results as well
as the results of ex vivo autoradiography, and showed the
feasibility of noninvasive MMP activity detection (Fig. 3).
Angiogenesis in plaque
Angiogenesis in atherosclerotic plaque may cause intra-
plaque haemorrhage and therefore contribute to more risk
of plaque rupture. Imaging of angiogenesis with specific
tracers which are avid to angiogenic factors, by SPECT or
SPECT/CT, can also reveal valuable information on plaque.
Imaging of intraplaque haemorrhage, if possible, will also
provide valuable information on plaque vulnerability.
Davies et al. showed that a proportion of Annexin V
uptake in atherosclerotic plaque is due to red blood cell
remnants in the plaque after intraplaque haemorrhage [113].
1772 Eur J Nucl Med Mol Imaging (2010) 37:1766–1777However, specific tracers for tracking bleeding within the
plaques have not yet been developed.
CT applications
Myocardial application
MicroCT studies of the heart need blood-pool imaging to
make the heart contour clear. Iodinated triglyceride isa blood-
pool agent that remains in the blood for hours and is cleared
slowly through the hepatobiliary systems. This contrast agent,
due to its long circulation time, provides the opportunity to
select the best postinjection time points for imaging and
inducesgoodcontrastenhancementbetweenmyocardiumand
blood (500 HU) [114, 115]. Mukundan et al. [116]s t u d i e d
another iodinated agent for microCT which showed more
contrast enhancement between myocardium and blood in the
LV (650–700 HU). In another study, a novel polymer-coated
Bi2S3 nanoparticle (BPNP) was used as contrast agent for
CT scanning in mice. This agent showed high stability, high
x-ray absorption (fivefold more than that of iodinated
agents), and more than 2 hours of circulation time. CT scan
of mice using BPNP as contrast agent showed clear
delineation of ventricles and vascular structures [117].
In order to evaluate remodelling processes after MI in
mouse models, Detombe et al. used retrospective gated
microCT [118]. The ability to obtain dynamic images, and
short scanning times (<1 min), quantification, and the
ability to monitor the same animal during a longitudinal
study are promising results of this study. More investiga-
tions in the future using hybrid imaging systems (e.g.
microSPECT and microCT) will add more dimensions to
current preclinical studies.
Vascular dynamics
To investigate the dynamics of myocardial microvessels,
BaSO4 contrast microCT has been used for 3-D visualiza-
tion of the capacitance of intramyocardial vessels during
systole and diastole [119]. In this study, the 3-D architec-
ture of microvessels was demonstrated. Images also showed
that the vascular volume fraction is decreased from diastole
to systole by 48%, but is not collapsed.
Vascular calcification
Atherosclerotic plaque calcification is correlated with total
plaque burden and future cardiovascular events [120].
Exploring the underlying pathology of plaque calcification
will suggest the direction for future interventions. It has
been shown that formation and progression of plaque
calcification is correlated with inflammation and apoptosis
in atherosclerotic plaques [120, 121]. Interestingly, it has
In vivo
CT
SPECT
Fusion
Transverse Sagittal Transverse Sagittal Frontal Frontal
Arch
Bifurcation
Ex vivo
0hr (Blood pool image) 4hr 
Fig. 3 Uptake of RP805 (a broad-spectrum MMP ligand) demon-
strating MMP expression in an atherosclerotic rabbit on an
uninterrupted diet. The three columns display transverse, sagittal,
and frontal projections, and the three rows display microCT,
microSPECT, and fusion images. The left set of three columns
displays images immediately (0 h) after radiotracer administration
(representing blood pool images), and the right set of three columns
displays images obtained at 4 h (representing tracer uptake in target
tissue). The images were adapted from reference [74]
Eur J Nucl Med Mol Imaging (2010) 37:1766–1777 1773been shown that microCT can detect plaque calcification in
small rodents [104, 122]. Isobe et al. demonstrated the
feasibility of microCT images in detecting plaque calcifi-
cation in the aorta [104]. Although, they used
99mTc-
annexin microSPECT/CT to detect apoptosis in ApoE
−/−
mice they did not investigate the correlation between
calcification and tracer uptake. Further studies using
SPECT/CT to correlate different parameters of plaque
vulnerability, using SPECT, with calcification, detected by
CT, can offer a better understanding on the pathology
underlying plaque calcification.
Vascular wall calcification in rodents can also be detected
by microCT. In one study on uraemic mice, which have been
shown to be a suitable model for vascular calcification,
calcification of the aorta was detected and quantified by
microCT [123]. The quantification results proved to be
reproducible and well-correlated with ex-vivo histological
evaluation. This may provide investigators with a promising
technique to follow-up and monitor the effects of therapies
aiming to reverse vascular calcification in patients with
chronic renal failure.
Conclusion
MicroSPECT and microSPECT/CT are powerful tools for
elucidating fundamental pathophysiological pathways of
heart diseases. They provide information on cardiovascular
processes at the molecular and cellular levels. They also
offer the opportunity to monitor pharmacological and
biological therapeutic interventions in preclinical investiga-
tions. Moreover, studies on radiotracer development for
detecting new aspects of cardiovascular pathophysiological
processes can be investigated in experimental models of
cardiovascular pathology. The recent development of
hybrid imaging systems, besides providing technical
improvements in image quality, adds phenotypic data to
functional radionuclide imaging information.
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